Earlier this week, federal regulators continued their efforts to combat the spread of products featuring allegedly false and misleading claims that products can diagnose, treat, cure, or prevent COVID-19. In warning letters issued to CBD Gaze, Alternavita, Musthavemom.com
Continue Reading FDA and FTC Joint Warning Letters Target Amazon Affiliates Making False COVID-19 Claims
The Proof Is In The Product: National Advertising Division (NAD) Recommends CBD Company Discontinue Claims
On April 29, the National Advertising Division (“NAD”) recommended that Talyoni Professional, LLC and its affiliate, Ecoco, Inc. (collectively “Talyoni”) discontinue express claims that the companies’ cosmetic and wellness products contain CBD, as well as product performance claims based on
Continue Reading The Proof Is In The Product: National Advertising Division (NAD) Recommends CBD Company Discontinue Claims
Florida Court Permits CBD Mislabeling Case to Proceed
In a somewhat mixed decision for cannabis company defendants, a false advertising class action lawsuit will proceed in the Southern District of Florida – and not be halted while waiting for guidance from the FDA – although some of the
Continue Reading Florida Court Permits CBD Mislabeling Case to Proceed
New York Joins the CBD COVID-19 Enforcement Fray
As we have written about here and on our sister blog, Ad Law Access, regulators have wasted no time in taking enforcement actions against companies’ alleged false marketing around COVID-19. Just today, the Office of the New York Attorney
Continue Reading New York Joins the CBD COVID-19 Enforcement Fray
Federal Relief Loans Available Now for Hemp Businesses Suffering from COVID-19 Economic Impacts
Legal hemp businesses suffering from the economic devastation caused by coronavirus are eligible for emergency aid programs included in the $2.2 trillion federal economic stimulus package – and can start applying for that monetary relief immediately.
While medical and recreational
Continue Reading Federal Relief Loans Available Now for Hemp Businesses Suffering from COVID-19 Economic Impacts
CBD Manufacturer Not Immune From FDA Enforcement For COVID-19 Claims
In the midst of continued enforcement regarding coronavirus marketing, FDA sent a warning letter to NeuroXPF concerning advertising for its CBD products alleging that they can boost immune systems to help consumers avoid contracting the virus. Citing the need to
Continue Reading CBD Manufacturer Not Immune From FDA Enforcement For COVID-19 Claims
DEA Publishes Long Awaited Proposed Rules for Grower Licenses
In an important step intended to expand marijuana research, the Drug Enforcement Administration (DEA) unveiled a long-awaited rule proposal last week that would permit the agency to issue additional growing licenses for research-grade cannabis.
The Notice of Proposed Rulemaking was
Continue Reading DEA Publishes Long Awaited Proposed Rules for Grower Licenses
Cannabis Companies Largely Deemed “Essential” During COVID-19 Pandemic
As the coronavirus pandemic spreads across the country, many businesses have closed temporarily under “stay-at-home” or “shelter-in-place” orders – but cannabis companies largely have been exempted from this trend.
A variety of different jurisdictions across the county have deemed cannabis
Continue Reading Cannabis Companies Largely Deemed “Essential” During COVID-19 Pandemic
KDW COVID-19 Resource Center Provides Critical Business Guidance
As the novel coronavirus (COVID-19) has reached pandemic levels, companies of all sizes and in all industries face myriad impacts to business operations and the health and well-being of employees.
To help clients navigate these new challenges, including the unpredictability
Continue Reading KDW COVID-19 Resource Center Provides Critical Business Guidance
Senate Approps Hearing Highlights USDA-DEA Friction and the 2021 Growing Season
USDA Secretary Sonny Perdue testified yesterday at a subcommittee hearing of the Senate Appropriations Committee. USDA’s 2021 budget request was the reason for the hearing, but there was also key discussion around the agency’s hemp rules. Excerpted highlights include the
Continue Reading Senate Approps Hearing Highlights USDA-DEA Friction and the 2021 Growing Season
FDA Sends CBD Status Report to Congress; Market Clarity Remains Elusive
Earlier this week, FDA sent its status report regarding a potential CBD enforcement discretion policy to Congress. As we wrote here, FDA was required to issue the report per the Joint Explanatory Statement attached to the 2020 Ag Appropriations
Continue Reading FDA Sends CBD Status Report to Congress; Market Clarity Remains Elusive